Related Experiment Video

Updated: Jul 20, 2025

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.5K

Influence and mechanism of sodium-glucose cotransporter-2 inhibitors on the cardiac function: study protocol for a

Min-Jia Cao1, Fang-Hong Shi1, Bin-Bin Yu2

  • 1Department of Pharmacy, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Frontiers in Endocrinology
|August 4, 2023
PubMed
Abstract

Insights

This study investigates if sodium-glucose cotransporter-2 (SGLT2) inhibitors improve heart function after acute myocardial infarction (AMI). It assesses left ventricular function and quality of life in patients with type 2 diabetes mellitus, exploring cardioprotective mechanisms.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Acute myocardial infarction (AMI) is a major cause of heart failure and death.
  • Sodium-glucose cotransporter-2 (SGLT2) inhibitors show cardiovascular benefits, but their role in AMI patients is unclear.
  • The mechanism of SGLT2 inhibitors, particularly their effect on left ventricular (LV) function, requires further investigation.

Purpose of the Study:

  • To evaluate the efficacy of SGLT2 inhibitors in improving LV function in AMI patients with type 2 diabetes mellitus (T2DM).
  • To assess the impact of SGLT2 inhibitors on quality of life and functional capacity in this patient population.
  • To explore the underlying cardioprotective mechanisms of SGLT2 inhibitors in AMI.

Main Methods:

  • A prospective, phase IV, open-label, single-center trial involving 120 AMI patients with T2DM.
  • Patients receiving SGLT2 inhibitors form the experimental group; others receive standard antidiabetic agents (control group).
  • Primary outcome: change in LV end-systolic volume index (LVESVi) via cardiac magnetic resonance (CMR) over 1 year. Secondary outcomes include LV parameters, quality of life (KCCQ-OS, EQ-5D), and biomarkers.

Main Results:

  • This section is to be filled after study completion.

Conclusions:

  • This section is to be filled after study completion.
Keywords:
SGLT2 inhibitorscardiac functioncardiac mechanismsdiabetesprospective cohort study without control

More Related Videos

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

657
Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

1.6K

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.9K
Secondary Active Transport01:55

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
121.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
234
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
206
Glucose Absorption Into the Small Intestine01:26

Glucose Absorption Into the Small Intestine

Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.8K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
622